Peter R Lindgren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter R Lindgren has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Jan I. Olofsson
Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
2 shared publications Jan-Åke Gustafsson
2 shared publicationsSari Mäkelä
2 shared publicationsStefan Cajander
2 shared publicationsTorbjörn Bäckström
2 shared publicationsC.-G. Mahlck
1 shared publication
Latest Publications
- 1 June 2004
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 221 (1-2) , 97-104
Estrogen and progesterone receptors in ovarian epithelial tumors
- 1 June 2004
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 221 (1-2) , 97-104
Estrogen and progesterone receptors in ovarian epithelial tumors
- 1 May 2004
- Published by Elsevier in Molecular and Cellular Endocrinology
Estrogen and progesterone receptors in ovarian epithelial tumors
- 1 May 2004
- Published by Elsevier in Molecular and Cellular Endocrinology
Estrogen and progesterone receptors in ovarian epithelial tumors
- 1 September 2002
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 21 (3) , 583-589
The pattern of estradiol and progesterone differs in serum and tissue of benign and malignant ovarian tumors.
Epidemiological studies have indicated a relationship between gonadal steroid hormones and ovarian cancer. A production of both estradiol and progesterone by ovarian cancers has been demonstrated. The local steroid concentrations and the putative relation to histopathological and clinical condition were investigated herein. Ovarian tissue, ovarian tumor cyst fluid, ovarian vein samples and peripheral serum concentrations of estradiol and progesterone in pre- and post-menopausal women, subdivided into groups with normal ovaries, benign, borderline and malignant ovarian tumors, were quantitatively assessed. Both ovarian tissue concentrations of estradiol and progesterone were more than 100-fold higher than in serum. Based on differences in concentrations between different ovarian tumor groups, the data is not coherent with the previously suggested increased production of estradiol and progesterone in ovarian cancer tissue, since post-menopausal women with ovarian cancer presented lower median tissue hormone levels, most pronounced between malignant and benign tumors; median (25 and 75 percentile) estradiol; 9.40 (6.67-15.50) vs 16.44 (12.49-23.20), p=0.02 and progesterone; 308 (240-575) vs 957 (553-1143) pmol/g wet weight, p<0.01, n=81. Lower concentrations of estradiol, but not progesterone, were found in ovarian cancer tissue, ovarian cyst fluid and peripheral serum in patients with FIGO stages 3 and 4 than in stages 1 and 2. The novel finding of a large ovarian tissue to serum difference of both estradiol and progesterone indicates an important role of ovarian tissue concentrations in tumor biology and raises the question of adequate doses of anti-hormonal therapy in women with ovarian cancer.
- 1 September 2002
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 21 (3) , 583-589
The pattern of estradiol and progesterone differs in serum and tissue of benign and malignant ovarian tumors.
Epidemiological studies have indicated a relationship between gonadal steroid hormones and ovarian cancer. A production of both estradiol and progesterone by ovarian cancers has been demonstrated. The local steroid concentrations and the putative relation to histopathological and clinical condition were investigated herein. Ovarian tissue, ovarian tumor cyst fluid, ovarian vein samples and peripheral serum concentrations of estradiol and progesterone in pre- and post-menopausal women, subdivided into groups with normal ovaries, benign, borderline and malignant ovarian tumors, were quantitatively assessed. Both ovarian tissue concentrations of estradiol and progesterone were more than 100-fold higher than in serum. Based on differences in concentrations between different ovarian tumor groups, the data is not coherent with the previously suggested increased production of estradiol and progesterone in ovarian cancer tissue, since post-menopausal women with ovarian cancer presented lower median tissue hormone levels, most pronounced between malignant and benign tumors; median (25 and 75 percentile) estradiol; 9.40 (6.67-15.50) vs 16.44 (12.49-23.20), p=0.02 and progesterone; 308 (240-575) vs 957 (553-1143) pmol/g wet weight, p<0.01, n=81. Lower concentrations of estradiol, but not progesterone, were found in ovarian cancer tissue, ovarian cyst fluid and peripheral serum in patients with FIGO stages 3 and 4 than in stages 1 and 2. The novel finding of a large ovarian tissue to serum difference of both estradiol and progesterone indicates an important role of ovarian tissue concentrations in tumor biology and raises the question of adequate doses of anti-hormonal therapy in women with ovarian cancer.